CIL Announces Breakthrough in Benzene Recovery, Addressing Cost, Environmental, and Supply Challenges for OLED Display Manufacturers
12.12.2024 09:00:00 CET | ACCESS Newswire | Press release
TEWKSBURY, MA / ACCESSWIRE / December 12, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has successfully developed and implemented a game-changing benzene-d6 recovery program, addressing major pain points for manufacturers of organic light-emitting diode (OLED) displays. This innovative service reduces costs, minimizes environmental impact, and conserves scarce deuterium supplies.
OLED display producers rely heavily on deuterated benzene (benzene-d6) as a critical starting material in their synthesis processes. However, this results in significant quantities of depleted benzene-d6, which is no longer usable but still retains considerable deuterium value. The disposal of such depleted material poses environmental challenges and substantial expenses.
CIL's benzene-recovery program offers a transformative solution. Customers can now return their depleted benzene-d6 to CIL, where it undergoes a proprietary re-enrichment process to restore it to virgin material quality. This service is available at a significant cost savings compared to new benzene-d6, providing significant economic benefits.
Beyond the financial advantages, the program has far-reaching environmental and supply implications. It eliminates the need for costly disposal, reduces the demand on increasingly scarce deuterium (derived from heavy water, D2O) and conserves this vital resource for its growing applications in science, medical diagnostics, pharmaceuticals, and semiconductor production.
Recycling offers several sustainable benefits. It reduces pollution by releasing fewer chemicals into the environment. Recycling also saves energy, as reprocessing chemicals like benzene requires less energy than producing them from raw materials. This leads to lower greenhouse gas emissions, helping to combat climate change.
"This initiative underscores CIL's commitment to collaboration and innovation in addressing our customers' most pressing challenges," said Cliff Caldwell, CEO of CIL. "By recovering and re-enriching depleted benzene-d6, we create a circular economy approach that is both economically and environmentally sustainable. As the world's largest supplier of benzene-d6, we are uniquely positioned to deliver this groundbreaking service."
CIL's benzene recovery program is the result of 12 months of dedicated development, expansion, and rigorous testing to ensure reliable capacity and uncompromising quality. CIL invites interested parties to inquire about the program's details and how to participate.
About Cambridge Isotope Laboratories, Inc.
CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX, located in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com.
Contact Information
Crissy Krisko
crissyk@isotope.com
1.978.269.1930
SOURCE: Cambridge Isotope Laboratories, Inc.
View the original press release on accesswire.com
Cambridge Isotope Laboratories, Inc.

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
RE Royalties Announces Second Tranche Investment of $800,000 in Solaris Energy's U.S. Distributed Generation Solar Portfolio9.2.2026 23:00:00 CET | Press release
All amounts in US dollars unless otherwise stated. VANCOUVER, BC / ACCESS Newswire / February 9, 2026 / RE Royalties Ltd. (TSX.V:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce a further USD $800,000 investment toward the purchase of royalties on two portfolios of distributed generation ("DG") solar projects located throughout the United States being developed by Solaris Energy Inc. ("Solaris"). The Royalty Purchase for Portfolio 1 totals USD $4.8 million, of which USD $3 million was funded at closing, as announced on January 7, 2026. The Company expects to fund the remaining USD $1 million by Q2 2026, subject to the satisfaction of applicable conditions. The Royalty Purchase for Portfolio 2 is subject to the completion of due diligence to the satisfaction of the Company, other customary closing conditions, and is expected to occur later in the year, bringing the total portfolio level royalty investment to USD $9 million. The Royalty Rate will be adju
UK-Based Vesalic Limited Emerges from Stealth with Landmark Discovery of Potential Non-CNS Driver of Motor Neuron Diseases, including ALS, and Breakthrough Therapeutic and Diagnostic Opportunities9.2.2026 06:00:00 CET | Press release
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo in ALS patients, which is carried to the CNS, where it binds to and damages neurons Vesalic is pioneering a novel therapeutic to intercept and neutralise these toxins, potentially slowing or halting progression of monogenic and sporadic forms of ALS In addition, Vesalic has discovered a disease-specific alteration of the lipid composition in the membranes of exosomes circulating in the blood, and has developed a highly accurate biomarker-based technology to detect both monogenic and sporadic ALS Based on its novel biomarker discoveries, Vesalic is also applying its biomarker technology for other neurodegenerative diseases, including Alzheimer's and Parkinson's LONDON, UK / ACCESS Newswire / February 9, 2026 / Vesalic Limited, an early-stage neurodegenerative disease-focused biotech company, today emerged from stealth with the landmark discovery of a systemic process - largely
Innodata to Report Fourth Quarter and Fiscal Year 2025 Results5.2.2026 14:30:00 CET | Press release
NEW YORK, NY / ACCESS Newswire / February 5, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Fourth Quarter and Fiscal Year 2025 results after the market closes on Thursday, February 26, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+44) 800 279 7040 United Kingdom (+1) 289 819 1520 International Participant Access Code 27117 # Replay dial-In (+1) 888 660 6264 North America (+1) 289 819 1325 International: Replay Passcode 27117 # Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be av
Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release
Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom